Today: 21 May 2026
Browse Category

NASDAQ:CRMD 12 November 2025

CorMedix (CRMD) Q3 2025: Net Income Hits $108.6M, FY25 Guidance Raised to $390–$410M — Nov 12, 2025

CorMedix (CRMD) Q3 2025: Net Income Hits $108.6M, FY25 Guidance Raised to $390–$410M — Nov 12, 2025

CorMedix Inc. reported Q3 2025 net revenue of $104.3 million and net income of $108.6 million, citing strong DefenCath demand and Melinta portfolio sales. The company raised full-year pro forma revenue guidance to $390–$410 million and expects $115–$135 million in Q4 net revenue. Integration of Melinta is ahead of schedule, with $30 million in synergies targeted by year-end. CorMedix is rebranding as “CorMedix Therapeutics.”
12 November 2025
·

Stock Market Today

  • Asian Shares Rise on Oil Price Drop and Nvidia's Strong AI-Driven Earnings
    May 21, 2026, 1:31 AM EDT. Asian shares surged Thursday, led by South Korea's Kospi gaining 8%, following Wall Street's AI-driven rally and easing bond market pressure. Nvidia's quarterly profit jumped over 200%, fueled by demand for its AI chips, boosting tech stocks like Samsung Electronics, which rose 7.5%, and SK Hynix, up 11.3%. Taiwan's Taiex added 3.9%, supported by TSMC's 3% increase. Japan's Nikkei climbed 3.6% aided by a 15% rise in exports. Oil prices fell sharply, with Brent down 5%, arousing hopes of renewed U.S.-Iran oil supply talks, before a partial rebound. U.S. stocks also recovered, with the S&P 500 up 1.1% as 10-year Treasury yields eased, reducing pressure on equities amid inflation and interest rate concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop